Spleen tyrosine kinase expression is correlated with human papillomavirus in head and neck cancer

•High SYK expression is observed in HPV-positive HNSCC tumors.•Inhibition of SYK can control HNSCC cell line proliferation and migration.•SYK inhibition reduces tumor burden in PDX models. Spleen tyrosine kinase (SYK) is a promoter of cell survival in a variety of cell types, including normal and ca...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oral oncology 2020-02, Vol.101, p.104529-104529, Article 104529
Hauptverfasser: Black, Morgan, Ghasemi, Farhad, Sun, Ren X., Stecho, William, Datti, Alessandro, Meens, Jalna, Pinto, Nicole, Ruicci, Kara M., Khan, M. Imran, Han, Myung Woul, Shaikh, Mushfiq, Yoo, John, Fung, Kevin, MacNeil, Danielle, Palma, David A., Winquist, Eric, Howlett, Christopher J., Mymryk, Joe S., Ailles, Laurie, Boutros, Paul C., Barrett, John W., Nichols, Anthony C.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•High SYK expression is observed in HPV-positive HNSCC tumors.•Inhibition of SYK can control HNSCC cell line proliferation and migration.•SYK inhibition reduces tumor burden in PDX models. Spleen tyrosine kinase (SYK) is a promoter of cell survival in a variety of cell types, including normal and cancerous epithelial cells. We hypothesized that SYK would an important therapeutic target to inhibit for the treatment of HNSCC. SYK protein abundance in patient tumours was evaluated. SYK protein and mRNA abundance was used to examine patient survival and human papillomavirus (HPV) status. Small-interfering RNAs and gene editing with CRISPR/Cas9 were used to evaluate SYK expression on proliferation in HNSCC cell lines. The potency of SYK inhibitor ER27319 maleate on cellular proliferation was tested using a panel of 28 HNSCC cell lines and in vivo in HNSCC patient-derived xenograft (PDX) models. Moderate to high protein expression of SYK was observed in 24% of patient tumors and high SYK expression was exclusively observed in HPV-positive samples (p 
ISSN:1368-8375
1879-0593
DOI:10.1016/j.oraloncology.2019.104529